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Abstract
Objective: Schizophrenia, a neuropsychiatric disorder, is known to be neurodevelopmentally progressive.
Due to the extensive interindividual variability found in the responses of patients, management of schizophrenia
has proven to be challenging. This interindividual variability to treatment could be justified by the variation of the
enzymes in charge of metabolizing medications, especially those associated with cytochrome P450. Since genetic
factors influence the phenotypic responses to drugs, researchers are involved in identifying schizophrenic genetic
factors, which could impact responses and severe effects for commonly known neuroleptic drugs known as
pharmacogenetics. In order to predict drug response at the personal level, genetic variants that determine drug
effects need to be identified.
Methods: We have chosen to investigate gene targets for risperidone and clozapine, two commonly administered
drugs for the treatment of schizophrenia. The aim of this review is to contribute in the understanding of genetic
influences on drug responses of risperidone and clozapine in schizophrenia. We reviewed original primary research
articles, meta-analysis, and review publications on drug and gene interaction on the treatment of schizophrenia. Our
main findings focused on schizophrenia, pharmacogenetics and cytochrome P450.
Results and conclusion: After filtering our results to human species and English language, a total of 45
scientific articles were used for this review. A promising direction for future research in schizophrenia treatment lies
behind the identification of the specific genetic contributors that affect drug response.

Keywords: Schizophrenia; Pharmacogenetics; Cytochrome p450;
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approach has been used in order to develop drug compounds that
exhibit a mean average response from the population, which usually
results in large interindividual variation in the way that patients
respond to specific drugs [7].

Schizophrenia and/or treatment

Cytochrome p450 (CYP)

The debilitating disease schizophrenia, which affects millions
of people, is a chronic, neuropsychiatric disorder, considered
neurodevelopmentally progressive, and ranks as one of the 20 major
factors for disability in the world [1,2]. Schizophrenia is also considered
a complex disorder that cannot be described as a single developmental,
degenerative process because of how challenging it is to be diagnosed
and treated [1,3]. Statistically, individuals with one immediate family
member affected with the disease are usually 10 times more prone to be
affected with schizophrenia, while individuals with both parents affected
with the disease are around 50 times more likely to also be affected [4].
Moreover, unlike the plaques and tangles that characterize Alzheimer’s
disease, the brain abnormalities found in schizophrenic patients do not
usually contribute to a diagnosis [4]. Today, schizophrenia is usually
treated with antipsychotic medications either first generation, also
known as typical, or second generation, known as atypical. Although,
both categories block dopamine receptors, the second generation drugs
also affect serotonin levels. The use of these medications could result
in increased morbidity, which includes extrapyramidal-like symptoms,
weight gain, and rigidity [5]. Typical antipsychotics generally treat
positive symptoms associated with schizophrenia but these types of
medications are also found to cause unwelcome motor side effects. In
comparison, atypical antipsychotics have the ability to effectively treat
both positive and negative symptoms associated with schizophrenia,
but may also lead to severe metabolic side effects [6]. Despite the large
availability of resources in the medical field, physicians still struggle to
produce rational treatment options. Consequently, the trial and error
method is utilized and usually results in patient suffering, high cost, and
stress on the patient and the patient’s family [7]. Previously, a traditional

Due to the extensive interindividual variability found in the
responses of patients, management of schizophrenia has proven to
be challenging [3]. This interindividual variability to treatment could
possibly be justified by the variation of the enzymes in charge of
metabolizing medications, especially the enzyme system associated with
cytochrome P450 (CYP), which is composed of the major enzymes in
charge of the entire metabolic process [3,8,9]. This system is made up of
a family of isoenzymes, which are located in the inner membrane of the
mitochondria or the smooth endoplasmic reticulum of cells, especially
in the liver [10]. The major enzymes that have been identified from
the CYP family include CYP1A2, CYP2D6, CYP3A4 and CYP2C19.
These enzymes are coded by highly polymorphic genes [11]. For
instance, CYP2D6 contains over 60 alleles and 130 genetic variations
due to combinations of single nucleotide polymorphisms (SNPs) and
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copy number variations. This gene is found to be highly polymorphic.
CYP2D6, along with the other variants of the CYP family, metabolize
different types of antipsychotics [12]. Moreover, out of five main
CYP genes, the function of CYP2D6 is to metabolize several existing
prescribed antipsychotics as well as antidepressants and anxiolytics. The
CYP2D6 is one of the major genes in drug metabolism and it is located
on chromosome 22 [6]. Many antipsychotic drugs are considered
lipophilic compounds and require extensive metabolic energy in
order to be excreted from the body [13]. Approximately 20-25% of
clinically used medications are metabolized by the enzyme CYP2D6
[14]. Furthermore, a genetic impairment in CYP2D6 contributes to the
development of extrapyramidal side-effects, which usually result from
long-term schizophrenic treatment [12]. Additionally, the amount of
drug concentration is based on the rate at which enzymes metabolize
it, which is affected by genetic polymorphisms. Consequently, lower
rates of enzymatic activity will likely result in higher concentrations of
the drug and the possibility of adverse drug responses, while a higher
rate of enzymatic activity can result in a decrease of plasma levels and
diminished drug effects [6].

Pharmacogenetics
Since genetic factors influence the phenotypic responses to drugs,
an increasing number of researchers are involved in identifying
schizophrenic genetic factors for the disorder and treatment responses
for commonly known neuroleptic drugs [15,16]. This is where the field of
pharmacogenetics plays a major role. Pharmacogenetics focuses on the
relationship between the pharmacokinetic level or the pharmacodynamic
level and interindividual differences [15]. The pharmacokinetics focuses
on the way drugs being metabolized based on individual genetic
differences, while pharmacodynamics is to elucidate the differences in
responses among individuals [15]. Pharmacogenetics also focuses on
variations found in the human genome and in the different ways in which
individuals respond to drugs based on genetic factors [17]. Despite the
fact that there is a large variety of available medications, as many as 3050% of the patients with treatment of antidepressants and antipsychotics
will not adequately respond to treatment [16]. In order to predict drug
response at the personal level, genetic variants that determine drug effects
need to be identified [15]. Therefore, pharmacogenetics is to understand
individual differences within humans to help identify potential variants
in order to help formulate an individualized care for patients using
antipsychotic medications [8]. Recent scientific advancements, such
as the Human Genome Project, cutting edge technology and methods
of DNA analysis progress, have introduced new tools that aid in the
identification of genetic variation focusing on a drug target level. Giving
a new perspective for the field of pharmacogenetics [15], a large number
of research studies has been conducted. Although a vast amount of
genetic variation has been depicted regarding responses to certain
pharmaceutical medications, genetic tools are not able to identify the
likelihood of an individualized response to treatment. Consequently,
there is difficulty in establishing personalized drug therapies with
favorable options regarding medication and dosage. Despite the
development of expedient and more effective methods in genetic testing,
clinical application in the use of pharmacogenetics as a guide for therapy
may only be possible through the availability of a reliable predictor for
clinical outcomes [16].

Drugs
In order to appropriately select genes to investigate, familiarity with
a specific drug's mechanism of action must be known. Consequently,
there is an inclination to study well known drug targets [7]. Therefore,
we have chosen to investigate gene targets for risperidone and clozapine,
Bipolar Disord, an open access journal
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two commonly administered drugs for the treatment of schizophrenia.
“Risperidone is a widely prescribed antipsychotic for the treatment
of schizophrenia, with a relatively high rate of non-effectiveness or
intolerable side effects” [18]. Due to the unwelcoming side effects,
there is a high occurrence of risperidone non-compliance [18]. Some
common examples of these side effects include “extrapyramidal
symptoms (EPS), hyperprolactinemia, hyperlipidemia, weight gain,
and metabolic syndrome” [18]. On the other hand, clozapine, compared
to the other atypical antipsychotics, has been shown to be effective in
30-60% of schizophrenia patients [6]. “Clozapine is the drug of choice
for the management of treatment-resistant schizophrenia (TRS)
because of its superior clinical efficacy, its ability to reduce suicidal
risk, and its low propensity to produce movement disorders” [19].
In addition, since clozapine is able to interact with various serotonin
and dopamine receptors, it is speculated to yield antipsychotic effects.
However, the mechanisms are not yet clear [6]. Hence, knowledge and
understanding of the behavior of specific genes that affect risperidone
and clozapine treatment is of the utmost importance in order to guide
the personalization of prescribing the optimal medication for each
individual patient afflicted with schizophrenia [8].
The aim of this review is to understand genetic influences on
drug responses in schizophrenia. To aid in the development of a
pharmacogenetic test that would allow for the personalization of
antipsychotic drugs in the hopes of reducing undesirable side effects [7].
Lastly, to provide an updated overview on risperidone and clozapine to
guide physicians and clinical scientists in their clinical practice in order
to reduce toxicity, increase efficacy and reduce the overall cost based on
genotypes of each individual patient.

Methods
The primary aim of this review is to understand genetic influences
on drug response in schizophrenia. There were a total of 52 publications
with all five keywords (schizophrenia, pharmacogenetics, cytochrome
P450, treatment, and psychiatric disorders (Figure 1). We then filtered
for the Human species and the English language and identified a total of
45 publications. After further filtering for free full text, 10 publications
were identified. We assessed all 10 publications and identified 25
candidate genes and selected eight of those candidate genes and
their polymorphisms. The eight genes selected include Cytochrome
P450 2D6 (CYP2D6), Catechol-O-methyltransferase (COMT),
5-Hydroxytryptamine transporter (5HTT), 5-Hydroxytryptamine
receptor 6 (5HT6), 5-Hydroxytryptamine receptor 2A (HTR2A),
5-Hydroxytryptamine receptor 2C (HTR2C), Dopamine receptor
D2 (DRD2) and Dopamine receptor D3 (DRD3). These genes were
selected because they were the most prominent in our search in relation
to clozapine and risperidone treatment.

Results
After filtering steps, we were focus on eight genes in association
with antipsychotic treatment responses for patients with schizophrenia
(Figure 1).

CYP2D6
The P450 enzyme system in the liver is the main system responsible
for drug metabolism. CYP2D6, located on chromosome 22q13.1, is one
of the major genes used by the system and it metabolizes around 20-25%
of all clinically used medications, including risperidone and clozapine
[20]. This gene is considered to be highly polymorphic. We discussed
four genetic variants involved in differences in treatment responses in
various populations (Table 1). Research shows that poor metabolizers
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Records identified through the PubMed database search using keywords of schizophrenia, pharmacogenetics,
cytochrome P450, treatment, and psychiatric disorders
(n=52)
↓
Additional filter for Human species and English language
(n=45)
↓
Additional filter for free full-text reviews asses for content selected as most relevant and recent
(n=10)
↓
25 candidate genes identified
↓
8 candidate genes selected
Figure 1: Workflow of publications used for this review paper.

Genes

Polymorphism

Population

Frequency

*3B (rs1135824)

A (n=75)
C (n=65)
H (n=49)
AS

0.000
0.000
0.000
N/A

*3B (rs35742686)

A (n=661)
C (n=503)
H
AS (n=504)

0.002
0.019
N/A
0.000

A (n=24)
C (n=32)
H (n=23)
AS (n=65)

0.063
0.242
0.065
0.002

*6 (rs5030655)

A (n=661)
C (n=503)
H
AS (n=504)

0.001
0.020
N/A
0.000

COMT

Val108Met (rs4680)

A (n=661)
C (n=503)
H
AS (n=504)

0.281
0.500
N/A
0.280

5HTT

5-HTTLPR (rs25531)

A (n=661)
C (n=503)
H
AS (n=504)

0.220
0.089
N/A
0.132

5HT6

C267T (rs1805054)

A (n=661)
C (n=503)
H
AS (n=504)

0.063
0.283
N/A
0.457

CYP2D6
*4 (rs3892097)

A (n=661)
C (n=503)
H
AS (n=504)

0.121
0.079
N/A
0.005

T102C (rs6313)

A (n=661)
C (n=503)
H
AS (n=504)

0.393
0.436
N/A
0.412

A-1438G (rs6311)

A (n=661)
C (n=503)
H
AS (n=504)

0.409
0.437
N/A
0.412

Cys23Ser (rs6318)

A (n=661)
C (n=503)
H
AS (n=504)

0.299
0.117
N/A
0.012

His452Tyr (rs6314)

HTR2A

HTR2C

Bipolar Disord, an open access journal
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Treatment Response

•
•

•
•
•

Antipsychotic

PMs tend to accumulate higher drug levels in blood, and theoretically, require
lower doses to achieve therapeutic effects (Kakihara et al. [21], n=136; Riedel et
al. [22], n=82)
Risperidone
UMs may require higher doses of an antipsychotic due to faster elimination of the
drug (Arranz and de Leon [23])

met/met genotype results in 3-4 fold lower enzyme activity compared with the val/
val allele pair (Zhang and Malhotra [20])
met/val heterozygote results in intermediate enzyme activity (Zhang and Malhotra [20])
val/val genotypes were less likely to respond to 8 weeks of clozapine treatment
(Bertolino et al. [34], n=59)

First generation
Antipsychotics
(FGAs)
and
Clozapine

•

Short allele is associated with poor response to clozapine and risperidone treatment Clozapine and
(Arranz et al. [25], n=200; Wang et al. [26], n=129; Dolzan et al. [27], n=56)
Risperidone

•

Significant association between the T/T genotype and better treatment response Clozapine and
(Yu et al. [28], n=99; Lane et al. [29], n=123; Zhang and Malhotra [20])
Risperidone

•
•

Ca+2 mobilization ↓ (Zhang and Malhotra [20])
Tyr variant is associated with reduced calcium release and reduced ability to
activate phospholipases (Zhang and Malhotra [20])
Tyr variant showed lowered antipsychotic binding affinity and ↓ drug potency
(Arranz et al. [35], n=274; Masellis et al. [31], n=185; Arranz et al. [36], n=153)
Tyr allele was significantly associated with poor response to clozapine treatment
compared to the His allele (Arranz et al. [35], n=274; Masellis et al. [31], n=185;
Arranz et al. [36], n=153)
Clozapine and
C allele of T102C was more prevalent among non-responders for Clozapine Risperidone
(Arranz et al. [35], n=274)
For risperidone response, there is a significant association between the C/C
genotype and better response (Lane et al. [37], n=100; Kim et al. [38], n=100)

•
•
•
•
•

G/G genotype was less likely to respond to clozapine (Arranz et al. [35], n=274,
Chen et al. [39], n=128)

•

Patients with Ser allele were more likely to respond to clozapine treatment
Clozapine
compared to patients who are Cys/Cys homozygotes (n=162)
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A (n=661)
C (n=503)
H
AS (n=504)

0.001
0.023
N/A
0.037

A (n=661)
C (n=503)
H
AS (n=504)

0.430
0.085
N/A
0.137

Taq1A (rs1800497)

A (n=661)
C (n=503)
H
AS (n=504)

0.385
0.188
N/A
0.406

Taq1B (rs1079597)

A (n=661)
C (n=503)
H
AS (n=504)

0.166
0.149
N/A
0.414

A-241G (rs1799978)

A (n=661)
C (n=503)
H
AS (n=504)

0.173
0.060
N/A
0.178

Ser9Gly (rs6280)

A (n=661)
C (n=503)
H
AS (n=504)

0.181
0.336
N/A
0.306

Ser311Cys (rs1801028)

-141C
(rs1799732)

DRD2

DRD3

Ins/Del

•
•

Inhibition of cAMP synthesis ↓ (Itokawa et al. [50], n=50)
Ser/Ser genotype is more likely to respond to risperidone treatment (Lane et al.
[29,49], n=123)

•

Del allele carriers had poor response to clozapine (Malhotra et al. [43], n=72) and
took longer time to respond to risperidone (Lencz et al. [44], n=61)
Patients with the Ins/Ins genotype are 54% more likely to respond to antipsychotic
drugs than those with at least one copy of the Del allele (Zhang et al. [45], n=687)

•
•

The A1 allele carriers were found to be more responsive to antipsychotic drugs Clozapine and
(Suzuki et al. [47], n=25; n=57; Ikeda et al. [30], n=166)
Risperidone

•

T allele is associated with a higher response rate in African Americans (Hwang et
al. [46], n=232)

•

In Asian samples, the A allele or A/A genotype was associated with better
improvement after risperidone treatment (Xing et al. [51], n=125; Ikeda et al. [30],
n=120) but took a long time to respond to risperidone in the American sample
(Lencz et al. [44], n=61)

•

The Gly 9 variant is associated with altered dopamine binding affinity and may ↑ Clozapine and
DRD3 densities in some brain areas (Jeanneteau et al. [52], n=276)
Risperidone

A: African, C: Caucasian and/or European, E: European, H: Hispanic, As: Asian, N/A: Not Available, n: sample size, FGA: First Generation Antipsychotic, PM: Poor
Metabolizer, IM: Intermediate Metabolizer, UM: Ultrarapid Metabolizer, EM: Extensive Metabolizer, Del: Deletion, Ins: Insertion
Table 1: Genetic variation of eight genes involved in differences in treatment responses in various populations.

(PMs) typically cause Risperidone build up in the blood. Thus, there is
a lower dose requirement to attain a therapeutic effect for PMs [21,22].
In contrast, ultra rapid metabolizers (UMs) are needed in higher doses
to produce a therapeutic effect [23]. Moreover, the (Table 1) also shows
difference of allele frequencies of CYP2D6-3B (rs35742686) between
the Caucasian (19%) and Africa and American population (2%) as
well as CYP2D6-4 (rs3892097) between the Caucasian (24%) and
Hispanic (6.5%) populations. Because of inter-ethnic heterogeneity, the
dosage established in a landmark trial and clinical pharmacogenetics
applications for a certain population may not be generalizable to other
ethnic populations and a follow-up study is often needed to find the
maximum tolerated dose for different populations. This problem even
exists in various ethnic sub-populations [24].

5HTT
Actions of antipsychotic medications are believed to be significantly
mediated by the serotonin system. Second generation antipsychotics
bind to the 2A serotonin receptors relative to the D2 dopamine receptors.
Therefore, different genetic variations have been studied in order to
examine their associations to drug responses. The gene responsible
for the serotonin transporter is known as 5HTT and is located on
chromosome 17q11.2. This transporter, an integral membrane protein,
allows for the entry of serotonin into presynaptic neurons. As a result,
serotonin is recycled in a sodium-dependent method [20]. In three
studies, one with a sample composed of 200 Caucasian participants
[25], one with a sample of 129 Chinese participants [26] and one with
a sample of 56 Caucasian participants [27], a deficient response was
associated with the short allele for the 5-HTTLPR polymorphism
for Clozapine and Risperidone treatment (Table 1). Again, there are
different allele frequencies of the 5-HTTLPR polymorphism among the
Africa American (22%), Caucasian (8.9%) and Asia (13%) populations.

5HT6
Other variants of the serotonin system have been associated with
drug efficacy, especially the 5HT6 gene. This gene codes for the 5HT6
serotonin receptor [20]. Two studies, one with a sample composed of
99 Chinese participants [28] and one with 123 Chinese participants
Bipolar Disord, an open access journal
ISSN: 2472-1077

[29] have shown a notable association among the T/T genotype and
an improved response to Clozapine and Risperidone treatment in Han
Chinese participants [28,29]. However, two other studies, one with 120
Japanese participants [30] and one with 173 Caucasian and African
American participants [31], did not show any association between the
treatment response and genetic variance of the 5HT6 gene (Table 1).

COMT
The COMT gene, located on chromosome 22q11.21, codes for
the catechol-O-methyltransferase (COMT) enzyme. Antipsychotic
drugs, such as Risperidone and Clozapine employ their effect on
the dopaminergic pathways. Because COMT is one of the major
enzymes responsible for dopamine clearance, it may be able to control
antipsychotic action [20]. Research has shown that there is decreased
enzyme activity by 3-4 folds in individuals expressing the met/met
genotype as compared to the val/val genotype [20]. When treated with
several first generation antipsychotics (FGAs), a case-control study
with 94 Caucasian participants showed that the met/met genotype
showed a decrease response to the treatment [32]. Furthermore, a
study with 86 Caucasian and African American participants confirmed
the previous findings and showed that individuals with the met allele
were found to exhibit a response to Clozapine and positively influence
cognitive functions [33]. Intermediate enzyme function is associated
with individuals heterozygous for met/val genotype [20]. However,
a study with a small sample size (59 Caucasian participants) showed
that individuals with a val/val genotype undergoing an eight-week long
treatment regimen were less likely to respond to Clozapine treatment
[34] (Table 1). Therefore, future replication and confirmation need to
valid these findings. In addition, the findings of COMT-Val108Met
(rs4680) also demonstrate ethnic variability in treatment response
phenotypes and different allele frequencies among three populations
(Table 1).

HTR2A
The gene HTR2A, located on chromosome 13q14-q21, codes for the
5-HT 2A receptor. This receptor is usually found in the cerebral cortex
and is often linked to the negative symptoms found in schizophrenia
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patients. According to Zhang and Malhotra [20], the polymorphism
His452Tyr is associated with a decrease in calcium mobilization, in
calcium release, and in activation of phospholipases. In in-vitro data,
the Tyr variant demonstrated a smaller drug binding affinity and
lowered Clozapine and Risperidone potency. Unlike the His allele, the
Tyr allele is correlated to a lowered response to Clozapine treatment in
three studies with 153 Caucasian participants [35], 185 Caucasian and
African American participants [31], and 274 Caucasian participants
[36]. Similarly, in a meta-analysis with 274 Caucasian participants, the
Tyr/Tyr genotype was correlated to a lowered response to Clozapine
[35]. For the T102C (rs6313) polymorphism, there was a higher
predominance of the C allele in non-responders undergoing Clozapine
treatment [35]. For Risperidone treatment, individuals with the C/C
genotype demonstrated an improved response in two studies with 100
Chinese participants [37] and 100 Korean participants [38]. For the
A-1438G (rs6311) polymorphism, individuals with the G/G genotype
were shown to exhibit a decreased response to Clozapine treatment
in two studies with 274 Caucasian participants [35] and 128 Chinese
participants [39] (Table 1).

HTR2C
The gene HTR2C, located on chromosome Xq24, codes for the
5-HT2C receptor. This receptor is usually found in the striatum,
prefrontal cortex, and limbic system and it has a role in several
pathways including memory, emotional processing, appetite, executive
and motor functioning [20]. For the Cys23Ser polymorphism, a study
with 162 Caucasian participants found that individuals with the Ser
allele, unlike those who were homozygous for the Cys/Cys allele, had
a higher rate of response to clozapine treatment [40]. However, three
more recent studies one with 152 Caucasian participants [41], one with
185 Caucasian and African American participants [31], and one with
163 Caucasian participants [42] disagreed with this finding (Table 1).
The current findings again suggest how complex and heterogeneity
of genetics and treatment responses of clozapine among patients
with schizophrenia. The contradictory findings might be due to the
differences of the technique or genotype methods and the criteria to
defined treatment responses used in different studies.

DRD2
The gene DRD2, located on chromosome 11q22, codes for
the dopamine D2 receptor [20]. In the -141C insertion/deletion
polymorphism, carriers of the deletion allele exhibited an undesirable
response to Clozapine in a study with 72 Caucasian and African
American participants [43]. Furthermore, these carriers also exhibited
a delayed response to Risperidone in a study with 61 Caucasian and
African American participants [44]. On the other hand, individuals with
the insertion/insertion genotype are more prone to exhibit a response
to antipsychotic medication compared to individuals with one or more
copies of the deletion allele in a meta-analysis with 687 participants
[45]. The second polymorphism of the gene, the Taq1B polymorphism,
particularly the T allele, has been linked to an increased response
rate in African Americans in a study with 232 Caucasian and African
American participants [46]. Carriers of the third polymorphism,
Taq1A, showed a higher response to antipsychotic medications in three
different studies, one with 25 Japanese participants [47], one with 57
Caucasian participants [48] and one with 120 Japanese participants
[30]. Individuals with the Ser311Cys polymorphism, the fourth
polymorphism of the gene, specifically the Ser/Ser genotype, were
prone to respond to Risperidone treatment in a study with 123 Chinese
participants [49] and demonstrated a decrease in cAMP synthesis
inhibition in a study with 50 Japanese participants [50]. For the A-241G
Bipolar Disord, an open access journal
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polymorphism, Asian individuals with A allele or A/A genotype
showed a positive improvement to Risperidone treatment in a study
with 125 Chinese participants [51] and in study with 120 Japanese
participants [30]. However, American individuals with the A allele or
A/A genotype showed a delayed response to Risperidone treatment in a
study with 61 Caucasian and African American participants [44]. Since
these studies were conducted with different ethnic populations, slightly
contradictory findings may be due to different allele frequencies of the
markers in different ethnic populations (Table 1).

DRD3
The DRD3 gene, located on chromosome 3q13.3, codes for the D3
dopamine receptor. This receptor is usually associated with the limbic
system and basal ganglia. Because of its ability to inhibit spontaneous
neurotransmitter transcription, this receptor plays a major role in
neurotransmitter regulation [20]. For the Ser9Gly polymorphism, in
the DRD3 gene, the Gly 9 variant was found to increase the affinity
alteration of dopamine binding and seem to increase brain density in
areas where DRD3 is found in individuals with this variant in a study
with 30 French participants [52] (Table 1), however future study is
needed to confirm these findings.

Discussion
Schizophrenia, a neuropsychiatric disorder, is known to
be neurodevelopmentally progressive [1]. Due to the extensive
interindividual variability found in the responses of patients,
management of schizophrenia has proven to be challenging [3]. This
interindividual variability to treatment could possibly be justified by
the variation of the enzymes in charge of metabolizing medications,
especially the enzyme system associated with cytochrome P450
(CYP) [3]. Evidence exists for the critical role genetic factors play in
antipsychotic medication treatment response. Decades of investigations
and clinical studies are beginning to provide results that may soon be
translated into clinical practice. We evaluated over 51 publications
including reviews, meta-analyses, and original studies related to
clozapine and risperidone antipsychotic treatment for schizophrenia and
pharmacogenetics. We identified eight genes (CYP2D6, 5HTT, 5HT6,
COMT, HTR2A, HTR2C, DRD2 and DRD3) with likely associations
with treatment response that may be good candidates for translation
into clinical applications of pharmacogenetics. Moreover, we focused
on the frequency of genetic polymorphisms in specific populations
such as Caucasian/European, African American, Hispanic and Asian.
Both researchers in the field of pharmacogenetics and clinicians could
benefit from a greater awareness of genetic polymorphisms associated
with antipsychotic treatment response and their frequencies in different
populations.
Finally, there is a paucity of pharmacogenetics antipsychotic studies
in populations other than Caucasian and Asian. However, there is
sufficient evidence demonstrating ethnic variability in antipsychotic
response phenotypes with carriers of the identical polymorphisms
in the genes we reviewed. We can conclude that this evidence points
to polygenic influence with possible linkage disequilibrium affecting
treatment outcomes. In order to elucidate the cause of ethnic variability,
additional studies with diverse populations are needed and results
should be stratified by ethnicity. The potential for pharmacogenetics
to improve treatment outcomes in the realm of psychiatric diseases is
undoubtedly vast. A greater focus on population specific outcomes may
simplify the challenges remaining in the field.
Some of the major difficulties that we encountered for antipsychotic
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pharmacogenetic studies were linked to small sample sizes, insufficient
information on minority populations, and outdated studies on clozapine
and risperidone despite the fact that they are widely prescribed
antipsychotic medications for schizophrenia. Therefore, future
directions should be aimed towards 1) studies including larger sample
sizes, 2) studies including a larger sample of minority populations, such
as the Hispanics and other minorities, 3) studies focused on clozapine
and risperidone antipsychotic treatment response.
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